Longeveron (LGVN) Competitors

In the previous week, Adicet Bio had 5 more articles in the media than Longeveron. MarketBeat recorded 12 mentions for Adicet Bio and 7 mentions for Longeveron. Adicet Bio's average media sentiment score of 1.12 beat Longeveron's score of 0.00 indicating that Adicet Bio is being referred to more favorably in the news media.

Adicet Bio has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. Adicet Bio's return on equity of -74.90% beat Longeveron's return on equity.

Longeveron has higher revenue and earnings than Adicet Bio. Adicet Bio is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Longeveron currently has a consensus price target of $5.50, suggesting a potential upside of 643.34%. Adicet Bio has a consensus price target of $46.80, suggesting a potential upside of 458.47%. Given Longeveron's higher possible upside, equities analysts plainly believe Longeveron is more favorable than Adicet Bio.

Longeveron has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market. Comparatively, Adicet Bio has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market.

10.0% of Longeveron shares are held by institutional investors. Comparatively, 83.9% of Adicet Bio shares are held by institutional investors. 7.4% of Longeveron shares are held by company insiders. Comparatively, 3.4% of Adicet Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Longeveron had 4 more articles in the media than Rallybio. MarketBeat recorded 7 mentions for Longeveron and 3 mentions for Rallybio. Rallybio's average media sentiment score of 1.44 beat Longeveron's score of 0.00 indicating that Rallybio is being referred to more favorably in the media.

Rallybio has a net margin of -911.07% compared to Longeveron's net margin of -1,977.59%. Rallybio's return on equity of -40.53% beat Longeveron's return on equity.

Longeveron has a consensus price target of $5.50, suggesting a potential upside of 643.34%. Given Longeveron's stronger consensus rating and higher possible upside, analysts plainly believe Longeveron is more favorable than Rallybio.

Rallybio has higher earnings, but lower revenue than Longeveron. Rallybio is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

90.3% of Rallybio shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 10.3% of Rallybio shares are held by insiders. Comparatively, 7.4% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Rallybio has a beta of -0.9, suggesting that its stock price is 190% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market.

In the previous week, Telomir Pharmaceuticals and Telomir Pharmaceuticals both had 7 articles in the media. Telomir Pharmaceuticals' average media sentiment score of 0.01 beat Longeveron's score of 0.00 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Telomir Pharmaceuticals has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. Telomir Pharmaceuticals' return on equity of -98.73% beat Longeveron's return on equity.

Telomir Pharmaceuticals has higher earnings, but lower revenue than Longeveron. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

10.0% of Longeveron shares are owned by institutional investors. 16.4% of Telomir Pharmaceuticals shares are owned by insiders. Comparatively, 7.4% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Longeveron has a consensus price target of $5.50, indicating a potential upside of 643.34%. Given Longeveron's stronger consensus rating and higher possible upside, analysts plainly believe Longeveron is more favorable than Telomir Pharmaceuticals.

Telomir Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.31, indicating that its share price is 131% less volatile than the broader market.

Atara Biotherapeutics presently has a consensus price target of $9.50, suggesting a potential upside of 17.43%. Longeveron has a consensus price target of $5.50, suggesting a potential upside of 643.34%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than Atara Biotherapeutics.

Atara Biotherapeutics has a net margin of -269.42% compared to Longeveron's net margin of -1,977.59%. Atara Biotherapeutics' return on equity of -79.12% beat Longeveron's return on equity.

Atara Biotherapeutics has higher revenue and earnings than Longeveron. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by insiders. Comparatively, 7.4% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Atara Biotherapeutics and Atara Biotherapeutics both had 7 articles in the media. Longeveron's average media sentiment score of 0.00 beat Atara Biotherapeutics' score of -0.33 indicating that Longeveron is being referred to more favorably in the news media.

Atara Biotherapeutics has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.31, meaning that its stock price is 131% less volatile than the broader market.